International HIV/aids community demands to Roche pharma to renounce to its patent on Fuzeon.
Sign Now
Roche : An historical contempt be employed for greed
International HIV/aids community demands to Roche pharma to renounce to its patent on Fuzeon.
Last 3 of July, during a meeting with several organizations of people living with HIV/aids in South Korea, the president general director of Roche-Korea, Mr Uls Flueckiger asserted many sentences showing indeed its contempt towards people living with HIV/aids. During the same meeting, a patient in case of treatment failure who was in the urgent need to be put on Fuzeon, was part of it ; Mr Flueckiger, full of arrogance, simply refused to listen to his story.
When you have a Monopoly, no need to be human.
Last 28th of September, via a press release signed by many organizations of many countries, South-Korean activists have called the international HIV/aids community to join a global week of actions against the Swiss Big Pharma Roche, to protest against Roche Policy to break the negotiations on Fuzeon with South-Korean government instead of cutting its prices. Indeed, while South Korea proposed $18,000 for the Fuzeon, Roche wanted $22,000, per person and per year. In South Korea, where the GDP per capita is $20,000, Roche wants the same price than in a country like the United States, where the GDP is $46,000. Moreover, South Korea -- because it has been listed by the World Bank as a High Income country -- is not eligible to the Global Fund to fight HIV/aids, TB and malaria. That means that the Global Fund does not pay for the purchase of treatments. Refusing to cut its prices, with the excuse that Korea is able to pay, break the negotiations, and leave people living with HIV/aids in treatment failure without the drugs they need is simply deadly.
A global week of actions
To denounce Roches infamy, South Korean activists have called the international HIV/aids community to rally a week of actions (between the 1st and the 7th of october). Organizations of people living with HIV/aids have indeed denounced during this week of actions the behavior -- full of contempt and cynicism -- of Roche big pharma. The day after the announcement of this week of action, Roches first reaction has been to get in touch with Act Up-Paris.
While Roche straight away got in touch with North NGOs, as Act Up-Paris, it has, all the week long, pushed back the time when it would straightly get in touch with people living with HIV/aids in South Korea.
That is what Act Up-Pariss spokesperson who talk to the firm immediately denounced, and tried to link Roche to the South Korean activists. But, a week later, South Korean activists still not have been called by Roche while they used to demonstrate every single day in front of Roche Koreas head office (link to pictures). In Paris, the 3th of october, Act Up-Paris organized a demonstration in front of Roche-France head offices in Neuilly-sur-Seine. An hour after, a delegation was received by Deborah Szafir, the head of communication of Roche-France, who asserted : that the parent company in Basel was taking the commitment to find an acceptable arrangement on the prices. On Monday, within a release (only) sent to Act Up-Paris, Roche was not bringing up any proper answer to the questions asked by South Korean activists. The only answer brought by big pharma was to transfer the responsibility of the failure of the negotiations on Fuzeon on South Korean government.
Cynicism be employed for greed (costs of production and withdrawal from research in HIV/aids field)
Regarding the possibility for South Korea to issue a compulsory licence on Fuzeon, the president of Roche-Korea, Mr Flueckiger cynically asserted on the 3th of July, during the same meeting, that anyway South Korea have not had the possibility to produce Fuzeon and that the patent was not the problem.
Usually, to justify the very High cost of its drugs, Roche points up the cost of R&D. But, in July 2008, Roche announced that it was withdrawing its researches in the field of HIV/aids.
Nowadays, to justify the very High price of Fuzeon, Roche constantly points up the cost of the fusion inhibitor and its complexity to manufacture. The activist community has demanded to Roche to release on its costs of production, in the highest transparency and in the most exact way as possible. Indeed, if the Fuzeon is that complex and uninteresting to manufacture and sell, pharma should not be that reluctant to release precise figures. The reality, is only that Roche is not able to supply its drugs for all, and it is very difficult to believe that sells of Fuzeon are that uninteresting for Roche, when we know that in 2007, sells of Fuzeon netted $266,8 millions for the swiss giant.
Roches cynicism and its tendency to systematically abuse of its position of strength on people living with HIV/aids has already last to much time. If Roche has showed itself unable to take in consideration HIV/aids South Korean activistss claims, and to cut its prices in Korea,
we demand :
- to Roche to renounce to its patent on the Fuzeon since it is not in measure to supply it for everyone
- to the South Korean government to issue a CL on the Fuzeon, as well as on every single Roche HIVs treatment.
- that all the countries to issues CLs on Roche pharma drugs.
----
South Korea : Korea HIV/AIDS Network of Solidarity / Nanuri+, HIV/AIDS Human Rights Advocacy Group of Korea / Public Pharmaceutical Center / Solidarity for Lesbian Gay Bisexual Transgender Human Rights of Korea / Korean Gay Men's Human Rights Group / Sarangbang, Group for Human Rights / Health Right Network / Korean Federation of Medical Groups for Health Rights / Association of Korea Doctors for Health Rights / Association of Physicians for Humanism / Korea Dentists Association for Health Society / Korea Health and Medical Workers Union / Korean Pharmacists for Democratic Society / People's Solidarity for Social Progress / Intellectual Property Left / Korean Progressive Network Jinbonet / Korea Leukemia Patient Group / Solidarity for New Progressive Party / FOR PEOPLE PWLH GROUP (LOVE4ONE / South Korea) / NNHAP(Nopi Narara Hiv Aids Positive / South Korea) / Democratic Labor Party (South Korea) / Sexual Minority Committee of the Democratic Laber Party(South Korea) / Solidarity for People's Health Rights (South Korea) / Kapf (Korea HIV/AIDS Positive Federation, South Korea) / Solidarity ofHuman Rights Groups
Cameroon : MOCPAT / Positive generation
China : China Global Fund Watch Initiative
France : ACT UP-Paris / Aides / Avocats pour la santй dans le monde / Coalition PLUS
India : Global Health Advocates, India / Safe Sailors' Club - The Humsafar Trust
Marocco : ALCS-Maroc
Switzerland : Global Health Advocates, SW. /
Thailand : AIDS Access Foundation-Thailand / Thai Network of People living with HIV/AIDS
United States : ACT UP-New York / ACT UP Philadelphia / Health GAP, Student Global AIDS Campaign (SGAC)
International HIV/aids community demands to Roche pharma to renounce to its patent on Fuzeon.
Last 3 of July, during a meeting with several organizations of people living with HIV/aids in South Korea, the president general director of Roche-Korea, Mr Uls Flueckiger asserted many sentences showing indeed its contempt towards people living with HIV/aids. During the same meeting, a patient in case of treatment failure who was in the urgent need to be put on Fuzeon, was part of it ; Mr Flueckiger, full of arrogance, simply refused to listen to his story.
When you have a Monopoly, no need to be human.
Last 28th of September, via a press release signed by many organizations of many countries, South-Korean activists have called the international HIV/aids community to join a global week of actions against the Swiss Big Pharma Roche, to protest against Roche Policy to break the negotiations on Fuzeon with South-Korean government instead of cutting its prices. Indeed, while South Korea proposed $18,000 for the Fuzeon, Roche wanted $22,000, per person and per year. In South Korea, where the GDP per capita is $20,000, Roche wants the same price than in a country like the United States, where the GDP is $46,000. Moreover, South Korea -- because it has been listed by the World Bank as a High Income country -- is not eligible to the Global Fund to fight HIV/aids, TB and malaria. That means that the Global Fund does not pay for the purchase of treatments. Refusing to cut its prices, with the excuse that Korea is able to pay, break the negotiations, and leave people living with HIV/aids in treatment failure without the drugs they need is simply deadly.
A global week of actions
To denounce Roches infamy, South Korean activists have called the international HIV/aids community to rally a week of actions (between the 1st and the 7th of october). Organizations of people living with HIV/aids have indeed denounced during this week of actions the behavior -- full of contempt and cynicism -- of Roche big pharma. The day after the announcement of this week of action, Roches first reaction has been to get in touch with Act Up-Paris.
While Roche straight away got in touch with North NGOs, as Act Up-Paris, it has, all the week long, pushed back the time when it would straightly get in touch with people living with HIV/aids in South Korea.
That is what Act Up-Pariss spokesperson who talk to the firm immediately denounced, and tried to link Roche to the South Korean activists. But, a week later, South Korean activists still not have been called by Roche while they used to demonstrate every single day in front of Roche Koreas head office (link to pictures). In Paris, the 3th of october, Act Up-Paris organized a demonstration in front of Roche-France head offices in Neuilly-sur-Seine. An hour after, a delegation was received by Deborah Szafir, the head of communication of Roche-France, who asserted : that the parent company in Basel was taking the commitment to find an acceptable arrangement on the prices. On Monday, within a release (only) sent to Act Up-Paris, Roche was not bringing up any proper answer to the questions asked by South Korean activists. The only answer brought by big pharma was to transfer the responsibility of the failure of the negotiations on Fuzeon on South Korean government.
Cynicism be employed for greed (costs of production and withdrawal from research in HIV/aids field)
Regarding the possibility for South Korea to issue a compulsory licence on Fuzeon, the president of Roche-Korea, Mr Flueckiger cynically asserted on the 3th of July, during the same meeting, that anyway South Korea have not had the possibility to produce Fuzeon and that the patent was not the problem.
Usually, to justify the very High cost of its drugs, Roche points up the cost of R&D. But, in July 2008, Roche announced that it was withdrawing its researches in the field of HIV/aids.
Nowadays, to justify the very High price of Fuzeon, Roche constantly points up the cost of the fusion inhibitor and its complexity to manufacture. The activist community has demanded to Roche to release on its costs of production, in the highest transparency and in the most exact way as possible. Indeed, if the Fuzeon is that complex and uninteresting to manufacture and sell, pharma should not be that reluctant to release precise figures. The reality, is only that Roche is not able to supply its drugs for all, and it is very difficult to believe that sells of Fuzeon are that uninteresting for Roche, when we know that in 2007, sells of Fuzeon netted $266,8 millions for the swiss giant.
Roches cynicism and its tendency to systematically abuse of its position of strength on people living with HIV/aids has already last to much time. If Roche has showed itself unable to take in consideration HIV/aids South Korean activistss claims, and to cut its prices in Korea,
we demand :
- to Roche to renounce to its patent on the Fuzeon since it is not in measure to supply it for everyone
- to the South Korean government to issue a CL on the Fuzeon, as well as on every single Roche HIVs treatment.
- that all the countries to issues CLs on Roche pharma drugs.
----
South Korea : Korea HIV/AIDS Network of Solidarity / Nanuri+, HIV/AIDS Human Rights Advocacy Group of Korea / Public Pharmaceutical Center / Solidarity for Lesbian Gay Bisexual Transgender Human Rights of Korea / Korean Gay Men's Human Rights Group / Sarangbang, Group for Human Rights / Health Right Network / Korean Federation of Medical Groups for Health Rights / Association of Korea Doctors for Health Rights / Association of Physicians for Humanism / Korea Dentists Association for Health Society / Korea Health and Medical Workers Union / Korean Pharmacists for Democratic Society / People's Solidarity for Social Progress / Intellectual Property Left / Korean Progressive Network Jinbonet / Korea Leukemia Patient Group / Solidarity for New Progressive Party / FOR PEOPLE PWLH GROUP (LOVE4ONE / South Korea) / NNHAP(Nopi Narara Hiv Aids Positive / South Korea) / Democratic Labor Party (South Korea) / Sexual Minority Committee of the Democratic Laber Party(South Korea) / Solidarity for People's Health Rights (South Korea) / Kapf (Korea HIV/AIDS Positive Federation, South Korea) / Solidarity ofHuman Rights Groups
Cameroon : MOCPAT / Positive generation
China : China Global Fund Watch Initiative
France : ACT UP-Paris / Aides / Avocats pour la santй dans le monde / Coalition PLUS
India : Global Health Advocates, India / Safe Sailors' Club - The Humsafar Trust
Marocco : ALCS-Maroc
Switzerland : Global Health Advocates, SW. /
Thailand : AIDS Access Foundation-Thailand / Thai Network of People living with HIV/AIDS
United States : ACT UP-New York / ACT UP Philadelphia / Health GAP, Student Global AIDS Campaign (SGAC)
Sign The Petition
Continue with Google
OR
If you already have an account please sign in, otherwise register an account for free then sign the petition filling the fields below.
Email and password will be your account data, you will be able to sign other petitions after logging in.
Shoutbox
Goal
0 signatures
Goal: 50
Tags
No tags
Embed Codes
direct link
link for html
link for forum without title
link for forum with title
